病灶内利妥昔单抗联合自体血清治疗结膜MALT淋巴瘤
这项前瞻性2期试验评估病灶内注射利妥昔单抗联合自体血清治疗复发/难治性结膜惰性CD20+淋巴瘤的安全性和疗效。20例MALT型淋巴瘤患者入组,耐受性良好,总缓解率65%(95%CI 45-85),12例达完全缓解,中位随访42个月时12例无复发。
要点
- 病灶内利妥昔单抗联合自体血清治疗结膜MALT淋巴瘤耐受性良好,仅3例轻度局部反应。
- 总缓解率65%(95%CI 45-85),治疗结束时12例完全缓解、1例部分缓解。
- 9例加用自体血清者中4例缓解改善(3例完全缓解、1例部分缓解),局部复发再治疗可获再次持久缓解。
核心结论
- 病灶内利妥昔单抗是复发结膜MALT淋巴瘤安全且有效的治疗。
- 加用自体血清可在部分病例中改善缓解。
- 局部复发再治疗可产生第二次持久缓解。
研究设计与样本
- 前瞻性2期试验(NCT01514344),纳入20例复发/难治性结膜惰性CD20+淋巴瘤成人患者,其中MALT型。
- 患者接受每周病灶内利妥昔单抗注射共4次,随后每月注射共6次;对每周剂量无反应者加用500 μL自体血清。
- 评估安全性、活性及自体血清的抗肿瘤效应。
主要发现
- 耐受性极好,仅3例轻度局部反应。
- 每周注射后,11例肿瘤消退、8例疾病稳定、1例疾病进展。
- 9例接受自体血清,其中4例缓解改善(3例完全缓解、1例部分缓解)。
- 治疗结束时12例完全缓解、1例部分缓解,总缓解率65%(95%CI 45-85)。
- 中位随访42个月(范围10-78),12例无复发,5年无进展生存率和至下次治疗时间率分别为59%±11%和69%±11%。
关键数值与推荐
- 总缓解率65%(95%CI 45-85)。
- 5年无进展生存率59%±11%,5年至下次治疗时间率69%±11%。
- 中位随访42个月(范围10-78)。
- 自体血清剂量500 μL,用于对每周剂量无反应者。
临床怎么用
- 病灶内利妥昔单抗可作为复发结膜MALT淋巴瘤的治疗选择。
- 对每周剂量反应不佳者,可考虑加用自体血清。
- 局部复发患者可再次接受病灶内利妥昔单抗联合血清治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed/refractory indolent CD20+ lymphoma of the conjunctiva (NCT01514344). Patients received 4 weekly intralesional injections of rituximab, followed by 6 monthly injections; 500 μL of autologous serum was added to rituximab in patients with lymphoma unresponsive to weekly doses. Safety, activity, and antitumor effect of autologous serum were investigated. Twenty patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma were enrolled. Tolerability was excellent, with only 3 mild local reactions. After weekly injections, 11 patients achieved tumor regression, 8 had stable disease, and 1 experienced progressive disease; 9 patients received autologous serum, with response improvement in 4 cases (3 complete responses, 1 partial response). At the end of treatment, 12 patients achieved a complete remission, and 1 achieved a partial response, with an overall response rate of 65% (95% confidence interval, 45-85). At a median follow-up of 42 months (range, 10-78), 12 patients remain relapse free, with 5-year progression-free survival and time-to-next-treatment rates of 59% ± 11% and 69% ± 11%, respectively. Three patients with local relapse were retreated with intralesional rituximab and serum; 2 achieved a complete response that lasted 25+ and 38+ months. Thus, intralesional rituximab is a safe and active therapy in patients with relapsed conjunctival MALT lymphoma. The addition of autologous serum improves response in some cases. Retreatment of local relapses can result in a second durable remission.
引用
- Ferreri AJM, Sassone M, Miserocchi E, et al. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. Blood Adv. 2020. PMID: 32182364. doi:10.1182/bloodadvances.2020001459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。